Skip to main content
Supplement Research and Comparison WebsiteBest Price Guarantee
Supplement Research and Comparison Website

The use of probiotics can reduce the severity of experimental periodontitis in rats with metabolic syndrome: an immunoenzymatic and microtomographic study.

  • 2021-11-15
  • Journal of Periodontology 93(2)
    • Giselle A Silva
    • A. L. Moreira
    • P. Silva
    • S. L. Salvador
    • R. Casarin
    • R. M. Vicente
    • Graziele C. Ferreira
    • J. E. dos Santos
    • F. Furlaneto
    • M. Messora

Abstract

Background: This study evaluated the effects of Bifidobacterium animalis subsp. lactis HN019 (B. lactis HN019) in the development of periodontitis (PE), associated or not with metabolic syndrome, (MS) in rats.

Methods: Ninety-six rats were grouped according to a food protocol: high-fat diet for induction of MS or standard diet for the control groups (C). They were subdivided into groups with (+) and without (-) PE, receiving (*) or not (**) probiotic (PROB): C-**, CP-*, PE+**, PEP+*, MS- MSP-*, MSPE+**, and MSPEP+*. PROB administration started on the eighth week of the study and PE was induced on the 14th week by placing ligature on the animals' lower first molars. Euthanasia occurred in the 16th week. Biomolecular analyzes, immunoenzymatic assays, and microtomographic analyses were performed. The data obtained were analyzed statistically (P < 0.05).

Results: The PEP and MSPEP groups showed lower levels of alveolar bone loss when compared with the PE and MSPE groups, respectively (P < 0.05). The immunoenzymatic analysis showed higher levels of interleukin (IL)-1β and a higher receptor activator of NF-kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio in the MSPE group when compared with the MSPEP group (P < 0.05). The PEP group showed lower levels of tumor necrosis factor (TNF)-α and IL-6 when compared with the PE group. The use of PROB attenuated dyslipidemia parameters in animals with MS, with or without PE.

Conclusion: B. lactis HN019 reduced more significantly the severity of PE in rats with MS, modulating both systemic metabolic and immunoinflammatory parameters in periodontal tissues.

Keywords: metabolic syndrome; periodontitis; probiotics.

Research Insights

SupplementHealth OutcomeEffect TypeEffect Size
Bifidobacterium animalis subsp. lactis HN019Reduced Alveolar Bone ResorptionBeneficial
Moderate
Bifidobacterium animalis subsp. lactis HN019Reduced Dyslipidemia ParametersBeneficial
Moderate
Bifidobacterium animalis subsp. lactis HN019Reduced Interleukin-1β LevelsBeneficial
Small
Bifidobacterium animalis subsp. lactis HN019Reduced Interleukin-6 LevelsBeneficial
Small
Bifidobacterium animalis subsp. lactis HN019Reduced RANKL/OPG RatioBeneficial
Small
Bifidobacterium animalis subsp. lactis HN019Reduced TNF-α LevelsBeneficial
Small
Bifidobacterium lactis HN019Improved Immunoinflammatory MarkersBeneficial
Moderate
Bifidobacterium lactis HN019Reduced Dyslipidemia in Metabolic SyndromeBeneficial
Moderate
Bifidobacterium lactis HN019Reduced Inflammation LevelsBeneficial
Moderate
Bifidobacterium lactis HN019Reduced Severity of PeriodontitisBeneficial
Moderate
Back to top